BioSpace News Archive

The below transaction deals with allocation of share options:

In this capacity, Mr. Bergstein will be responsible for strategic planning, business development, capital market activities and related endeavors.

These results were selected for presentation at the Keystone “Bioenergetics and Metabolic Disease"" symposium from 21 to 25 January 2018 in Keystone, Colorado.

Arrowhead Pharmaceuticals announced underwritten public offering of 11,500,000 shares of its common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares.

The clearances expand the company’s offering for the blood testing market.

Dr. Dunsire is a proven leader in the biopharmaceutical industry with three decades of experience and a successful track record of growing businesses, fostering R&D and commercial development, and creating shareholder value.

The study authors concluded that significant improvements over a range of subjective and objective endpoints, including a reduction in the need for sinus surgery by 61%, suggest that the SINUVA Sinus Implant may play an important role in management of recurrent nasal polyps.

Acasti Pharma announced that the underwriters of its offering of 9,900,990 common shares, together with warrants to purchase up to 8,910,891 common shares (the “Offering”) have given notice to exercise their over-allotment option by purchasing an additional 766,179 common shares at a price of US$1.01 per share, for additional gross proceeds to Acasti of approximately US$773,000.

The issue of CDIs under the Placement will occur in two tranches.

California Life Sciences Association today commended the U.S. House and U.S. Senate’s action to suspend until December 2019 the job and innovation destroying 2.3% medical device excise tax levied on medical device firms.